<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04845893</url>
  </required_header>
  <id_info>
    <org_study_id>ISG-EWOss</org_study_id>
    <nct_id>NCT04845893</nct_id>
  </id_info>
  <brief_title>Observational Study on Skeletal Ewing's Sarcoma</brief_title>
  <acronym>EWOss</acronym>
  <official_title>Observational Study on Treatment of Skeletal Ewing Sarcoma at Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Italian Sarcoma Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational prospective trial aimed to collect the collect demographic, clinical, surgical,&#xD;
      pathological and molecular characteristics and treatment from patients affected by skeletal&#xD;
      Ewing Sarcoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Ewing sarcoma treatment is based on chemotherapy, surgery and radiotherapy. Chemotherapy,&#xD;
      performed with a combination of several drugs, is given as primary treatment before surgery.&#xD;
&#xD;
      Surgical intervention must be performed in all cases in which it is possible to obtain an&#xD;
      excision with free margins and with acceptable functional deficits. However, when, after&#xD;
      surgery in case of incomplete resection, post-operative radiotherapy is used, in order to&#xD;
      reduce the risk of local recurrence as much as possible.&#xD;
&#xD;
      Subsequently in the local treatment, a phase of maintenance chemotherapy is foreseen, the&#xD;
      intensity of which is modulated according to the response to induction therapy.&#xD;
&#xD;
      The treatments are carried out with different programs for patients with localized disease or&#xD;
      metastatic disease and derive from clinical trials carried out in the last 30 years.&#xD;
&#xD;
      These results are the result of national and international prospective trials which,&#xD;
      precisely due to the rarity of the disease, took many years to execute, and it is significant&#xD;
      to know that randomized studies were in very limited numbers, as almost all the studies were&#xD;
      represented by studies of uncontrolled phase II Improving treatments requires the expansion&#xD;
      of knowledge on the biological behavior of this tumor and the acquisition of as much&#xD;
      information as possible deriving from clinical experience.&#xD;
&#xD;
      For this reason, pending the definition of a new prospective randomized trial, which will&#xD;
      take time (approximately two years) to be made operational, it is considered useful from a&#xD;
      scientific point of view to prospectively collect data relating to new cases of Ewing's&#xD;
      sarcoma 'bone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">May 25, 2028</completion_date>
  <primary_completion_date type="Anticipated">May 25, 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>5 years Event Free Survival (EFS)</measure>
    <time_frame>5 years</time_frame>
    <description>Onset of any event (an event is the defined as disease recurrence, death for disease or any other cause)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>at 5 years</time_frame>
    <description>Time elapsed for the diagnosis to the death for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events related to the treatments in patients with age &gt;21 years at the time of diagnosis</measure>
    <time_frame>Every 3 weeks (Week 3, week 6, week 9, week 12, ...) up to 30 months</time_frame>
    <description>Number of Participants of age &gt;21 years with Treatment-Related Adverse Events as Assessed by CTCAE v5.0,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess baseline clinical and disease-specific factors with possible impact on survival analyses in the subpopulation with Ewing-like sarcoma</measure>
    <time_frame>Baseline</time_frame>
    <description>Collection of clinical pathological characteristics at disease presentation/diagnosis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ewing Sarcoma of Bone</condition>
  <arm_group>
    <arm_group_label>Skeletal Ewing Sarcoma</arm_group_label>
    <description>This cohort include patients affected by Ewing Sarcoma of bone, referred to participating Institutions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment of Ewings Sarcoma of bone according clinical practice (includes drugs, surgery, radiotherapy or any other received treatments)</intervention_name>
    <description>This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments</description>
    <arm_group_label>Skeletal Ewing Sarcoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Ewing's sarcoma of the bone or with Ewing-like sarcoma (round cell sarcoma&#xD;
        with fusion of the EWSR1 gene with others not of the Ewings' Tumor Sarcoma family, sarcoma&#xD;
        with Capicua Transcriptional Repressor (CIC) rearrangement or sarcoma with BCL6 corepressor&#xD;
        (BCOR) rearrangement&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Ewing's sarcoma of the bone&#xD;
&#xD;
          2. Diagnosis of Ewing-like sarcoma (round cell sarcoma with fusion of the EWSR1 gene with&#xD;
             others not of the ETS family, sarcoma with CIC rearrangement or sarcoma with BCOR&#xD;
             rearrangement)&#xD;
&#xD;
          3. Diagnosis of extraosseous Ewing's sarcoma for patients&#xD;
&#xD;
          4. Age at diagnosis &lt;50 years&#xD;
&#xD;
          5. Assessment of the extent of the disease at onset in accordance with the European&#xD;
             Society of Medical Oncology guidelines&#xD;
&#xD;
          6. Patients or parents oe guardians of minors who have given their written informed&#xD;
             consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Presence of comorbid factors who can compromise the compliance of the treatment plan or&#xD;
        the evaluation of the outcomes, including but not limited to organ pathologies that&#xD;
        contraindicate the use of chemotherapy and psychological or social conditions that do not&#xD;
        allow for adequate compliance treatment or adequate follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexia Bertuzzi, MD</last_name>
      <phone>+390282244540</phone>
      <email>alexia.bertuzzi@cancercenter.humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Alexia Bertuzzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - Unit of Medical Oncology</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maurizio Mascarin, MD</last_name>
      <phone>+390434659</phone>
      <phone_ext>536</phone_ext>
      <email>mascarin@cro.it</email>
    </contact>
    <investigator>
      <last_name>Maurizio Mascarin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.R.C.C. - Unit of Medical Oncology</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Grignani, MD</last_name>
      <phone>+39.011.9933</phone>
      <phone_ext>278</phone_ext>
      <email>giovanni.grignani@ircc.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Grignani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliero universitaria consorziale policlinico - bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco De Leonardis, MD</last_name>
      <phone>00390805592</phone>
      <phone_ext>137</phone_ext>
      <email>francesco.deleonardis@policlinico.ba.it</email>
    </contact>
    <investigator>
      <last_name>Francesco De Leonardis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico S. Orsola Malpighi di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arcangelo Prete, MD</last_name>
      <phone>+390516363</phone>
      <phone_ext>111</phone_ext>
      <email>tmoped@aosp.bo.it</email>
    </contact>
    <investigator>
      <last_name>Arcangelo Prete, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Meyer</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Tamburini, MD</last_name>
      <phone>+3905556</phone>
      <phone_ext>621</phone_ext>
      <email>a.tamburini@meyer.it</email>
    </contact>
    <investigator>
      <last_name>Angela Tamburini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carla Manzitti, MD</last_name>
      <email>carlamanzitti@gaslini.org</email>
    </contact>
    <investigator>
      <last_name>Carla Manzitti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FONDAZIONE IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rossella Bertulli, MD</last_name>
      <phone>0039022390</phone>
      <phone_ext>2804</phone_ext>
      <email>rossella.bertulli@istitutotumori.mi.it</email>
    </contact>
    <investigator>
      <last_name>Rossella Bertulli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FONDAZIONE IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Luksch, MD</last_name>
      <phone>02.2390</phone>
      <phone_ext>2648</phone_ext>
      <email>roberto.luksch@istitutotumori.mi.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Luksch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Pini</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Primo Andrea Daolio, MD</last_name>
      <phone>003902.58296</phone>
      <phone_ext>467</phone_ext>
      <email>primoandrea.daolio@asst-pini-cto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianni Bisogno, MD</last_name>
      <phone>039049-8211</phone>
      <phone_ext>461</phone_ext>
      <email>gianni.bisogno@unipd.it</email>
    </contact>
    <investigator>
      <last_name>Gianni Bisogno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ARNAS P. O. &quot;Civico e Benfratelli&quot;</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo D'Angelo, MD</last_name>
      <phone>039 091666</phone>
      <phone_ext>4316</phone_ext>
      <email>oncoematologia.ped@arnascivico.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Coccoli, MD</last_name>
      <phone>0039050992</phone>
      <phone_ext>840</phone_ext>
      <email>l.coccoli@ao-pisa.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Luca Coccoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambin Gesu'</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Maria Milano, MD</last_name>
      <phone>06 68591</phone>
      <phone_ext>111</phone_ext>
      <email>giuseppemaria.milano@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Maria Milano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena - IFO</name>
      <address>
        <city>Rome</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Virginia Ferraresi, MD</last_name>
      <phone>+39065266919</phone>
      <email>ferraresi@ifo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita - Unit of Paediatric Oncoematology</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franca Fagioli, MD</last_name>
      <phone>+39011313</phone>
      <phone_ext>5447</phone_ext>
      <email>franca.fagioli@unito.it</email>
    </contact>
    <investigator>
      <last_name>Franca Fagioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS materno infantile Burlo Garofolo</name>
      <address>
        <city>Trieste</city>
        <zip>34137</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Rabusin, MD</last_name>
      <phone>0403785</phone>
      <phone_ext>563</phone_ext>
      <email>rabusin@burlo.trieste.it</email>
    </contact>
    <investigator>
      <last_name>Marco Rabusin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Riggi N, Suvà ML, Stamenkovic I. Ewing's Sarcoma. N Engl J Med. 2021 Jan 14;384(2):154-164. doi: 10.1056/NEJMra2028910. Review.</citation>
    <PMID>33497548</PMID>
  </reference>
  <reference>
    <citation>Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee, PaedCan and ERN EURACAN. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv79-iv95. doi: 10.1093/annonc/mdy310.</citation>
    <PMID>30285218</PMID>
  </reference>
  <reference>
    <citation>Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, Kovar H, Grimer R, Whelan J, Claude L, Delattre O, Paulussen M, Picci P, Sundby Hall K, van den Berg H, Ladenstein R, Michon J, Hjorth L, Judson I, Luksch R, Bernstein ML, Marec-Bérard P, Brennan B, Craft AW, Womer RB, Juergens H, Oberlin O. Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. J Clin Oncol. 2015 Sep 20;33(27):3036-46. doi: 10.1200/JCO.2014.59.5256. Epub 2015 Aug 24. Review.</citation>
    <PMID>26304893</PMID>
  </reference>
  <reference>
    <citation>Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, Marcus K, Sailer S, Healey JH, Dormans JP, Weiss AR. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012 Nov 20;30(33):4148-54. doi: 10.1200/JCO.2011.41.5703. Epub 2012 Oct 22. Erratum in: J Clin Oncol. 2015 Mar 1;33(7):814. Dosage error in article text.</citation>
    <PMID>23091096</PMID>
  </reference>
  <reference>
    <citation>Ferrari S, Sundby Hall K, Luksch R, Tienghi A, Wiebe T, Fagioli F, Alvegard TA, Brach Del Prever A, Tamburini A, Alberghini M, Gandola L, Mercuri M, Capanna R, Mapelli S, Prete A, Carli M, Picci P, Barbieri E, Bacci G, Smeland S. Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ann Oncol. 2011 May;22(5):1221-1227. doi: 10.1093/annonc/mdq573. Epub 2010 Nov 8.</citation>
    <PMID>21059639</PMID>
  </reference>
  <reference>
    <citation>Luksch R, Tienghi A, Hall KS, Fagioli F, Picci P, Barbieri E, Gandola L, Eriksson M, Ruggieri P, Daolio P, Lindholm P, Prete A, Bisogno G, Tamburini A, Grignani G, Abate ME, Podda M, Smeland S, Ferrari S. Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation. Ann Oncol. 2012 Nov;23(11):2970-2976. doi: 10.1093/annonc/mds117. Epub 2012 Jul 5.</citation>
    <PMID>22771824</PMID>
  </reference>
  <reference>
    <citation>Dirksen U, Brennan B, Le Deley MC, Cozic N, van den Berg H, Bhadri V, Brichard B, Claude L, Craft A, Amler S, Gaspar N, Gelderblom H, Goldsby R, Gorlick R, Grier HE, Guinbretiere JM, Hauser P, Hjorth L, Janeway K, Juergens H, Judson I, Krailo M, Kruseova J, Kuehne T, Ladenstein R, Lervat C, Lessnick SL, Lewis I, Linassier C, Marec-Berard P, Marina N, Morland B, Pacquement H, Paulussen M, Randall RL, Ranft A, Le Teuff G, Wheatley K, Whelan J, Womer R, Oberlin O, Hawkins DS; Euro-E.W.I.N.G. 99 and Ewing 2008 Investigators. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. J Clin Oncol. 2019 Dec 1;37(34):3192-3202. doi: 10.1200/JCO.19.00915. Epub 2019 Sep 25.</citation>
    <PMID>31553693</PMID>
  </reference>
  <reference>
    <citation>Ladenstein R, Pötschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, van den Berg H, Dirksen U, Hjorth L, Michon J, Lewis I, Craft A, Jürgens H. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010 Jul 10;28(20):3284-91. doi: 10.1200/JCO.2009.22.9864. Epub 2010 Jun 14.</citation>
    <PMID>20547982</PMID>
  </reference>
  <reference>
    <citation>Whelan J, Le Deley MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N, Hawkins DS, Amler S, Bauer S, Bielack S, Blay JY, Burdach S, Castex MP, Dilloo D, Eggert A, Gelderblom H, Gentet JC, Hartmann W, Hassenpflug WA, Hjorth L, Jimenez M, Klingebiel T, Kontny U, Kruseova J, Ladenstein R, Laurence V, Lervat C, Marec-Berard P, Marreaud S, Michon J, Morland B, Paulussen M, Ranft A, Reichardt P, van den Berg H, Wheatley K, Judson I, Lewis I, Craft A, Juergens H, Oberlin O; Euro-E.W.I.N.G.99 and EWING-2008 Investigators. High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. J Clin Oncol. 2018 Sep 6:JCO2018782516. doi: 10.1200/JCO.2018.78.2516. [Epub ahead of print]</citation>
    <PMID>30188789</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ewing Sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not planned</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

